WO2023126821 - C1Q BINDING ASSAY
National phase entry:
Publication Number
WO/2023/126821
Publication Date
06.07.2023
International Application No.
PCT/IB2022/062796
International Filing Date
27.12.2022
Title **
[English]
C1Q BINDING ASSAY
[French]
DOSAGE DE LIAISON AU C1Q
Applicants **
CURATEQ BIOLOGICS PRIVATE LIMITED
Inventors
THEEYA, Nagaraja
REDDY M, Raghurami
LELLA, Ravi
DADKE, Disha
Priority Data
202141061460
29.12.2021
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2557 | |
| EPO | Filing, Examination, Granting | 15735 | |
| Japan | Filing, Examination, Granting | 2510 | |
| South Korea | Filing, Examination, Granting | 2830 | |
| USA | Filing, Examination, Granting | 6540 |
Total:
30,172
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides a C1q binding assay. The assay disclosed here determines theC1q binding affinity of antibody by using Biolayer interferometry (BLI) technique. The disclosed method does not require any labelling of antibody, and thus is a simple and robust method for determining the binding affinity of antibody to C1q protein. The binding affinity of an antibody to a C1q protein involves use of biosensors such as anti-Human Fab-CH1 (FAB2G) biosensors to capture and functionalize the antibody.[French]
La présente divulgation concerne un dosage de liaison au C1q. Le dosage divulgué détermine l'affinité de liaison au C1q d'anticorps à l'aide d'une technique d'interférométrie de biocouche (BLI). La méthode de l'invention ne nécessite aucun marquage d'anticorps, et constitue ainsi une méthode simple et robuste pour déterminer l'affinité de liaison de l'anticorps à une protéine C1q. L'affinité de liaison d'un anticorps à une protéine C1q implique l'utilisation de biocapteurs tels que des biocapteurs Fab-CH1 (FAB2G) anti-humains pour capturer et fonctionnaliser l'anticorps.